Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Pylera - labeled renal guidance
Product / population
Bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride (Pylera), oral capsule
Renal method
Renal impairment categories as defined by the cited product label
DailyMed / product prescribing information · Bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride (Pylera), oral capsule
Renal method: Renal impairment categories as defined by the cited product label Source date: DailyMed SPL version 4, posted Jul 01, 2026 Retrieved: 2026-11-07
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Renal guidance: 4.4 Severe Renal Impairment / 8.6 Renal Impairment
Severe renal impairment contraindicates the fixed bismuth/metronidazole/tetracycline product. Confirm the combination and renal status before prescribing an H. pylori regimen.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
